个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Gao Yan[1] * ; Liu Yizhen[2] * ; Wang Yafei[3] ; Zhang Qingyuan[4] ; Wu Depei[5] ; Ye Xu[6] ; Wu Jianqiu[7] ; Xu Wei[8] ; Zhou Jianfeng[9] ; Yang Yu[10] ; Cen Hong[11] ; Zhang Feng[12] ; Xiang Ying[13] ; Tang Xiaoqiong[14] ; Ding Kaiyang[15] ; Lin JinYing[16] ; Ma Lei[17] ; Wang Shunqing[18] ; Yu Hao[19] ; Zhao Yang[20] ; Song Bin[21] ; Lv Fangfang[2,*1] ; Huang Huiqiang[1,*2] ;
机构： [1]Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. [2]Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. [3]Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. [4]Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. [5]Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. [6]Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. [7]Department of Medical Oncology, Jiangsu Institute of Cancer Research, Jiangsu Red Cross Cancer Center, Jiangsu Cancer Hospital, the Affiliated Hospital of Nanjing Medical University, Nanjing, China. [8]Hematology Department, Jiangsu Province Hospital, Nanjing, China. [9]Hematology Department, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China. [10]Department of Lymphoma and Head and Neck Cancer, The Affiliated Tumor Hospital of Fujian Medical University, Fuzhou, Fujian Province, China. [11]Department of Hematology, Lymphoma and Pediatric Oncology, Guangxi Medical University Affiliated Tumor Hospital and Oncology Medical College, Nanning, China. [12]Department of Hematology, Anhui Oncology Hospital, Bengbu Medical College, Bengbu, China. [13]Department of Hematology and Oncology, Chongqing Cancer Hospital, Chongqing, China. [14]The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. [15]Department of Hematology, Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui Province, China. [16]Department of Hematology, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China. [17]Guangzhou Medical University Affiliated Tumor Hospital and Oncology Medical College, Nanning, China. [18]Department of Hematology, Guangzhou First People's Hospital, Guangzhou, Guangdong, China. [19]Department of Biostatistics, Nanjing Medical University, Nanjing, China. [20]Nanjing Baosida Pharmaceutical Technology Co., Ltd, Nanjing, China. [21]West China Hospital of Sichuan University, Sichuan, China.
出处：
DOI： 10.1002/cncr.34544
ISSN：

关键词： bendamustine DOR indolent B‐cell non‐Hodgkin lymphoma ORR PFS safety

摘要：
The optimal treatment strategy for refractory or relapse (R/R) indolent non-Hodgkin lymphoma (iNHL) has not been fully identified. This study aims to investigate the efficacy and tolerance of bendamustine hydrochloride developed in native Chinese corporation in the treatment of patients with R/R iNHL.A total of 101 patients from 19 centers were enrolled in this study from July 2016 to February 2019. Bendamustine hydrochloride (120 mg/m2 ) was given on days 1 and 2 of each 21-day treatment cycle for six planned cycles or up to eight cycles if tolerated. Parameters of efficacy and safety were analyzed.The median age of the patients was 53.44 (range, 24.4-74.6) years old. A total of 56 (55.44%) patients completed at least six treatment cycles, and the relative dose intensity was 93.78%. The overall response rate was 72.28%, and the median duration of response was 15.84 months (95% confidence interval [CI], 13.77-27.48 months). Median progression-free survival was 16.52 months (95% CI, 14.72-23.41 months), and the median overall survival was not reached. Grade 3 or 4 hematologic toxicities included neutropenia (77.22%), thrombocytopenia (29.70%), and anemia (15.84%). The most frequent nonhematologic adverse events (any grade) included nausea, vomiting, fatigue, fever, decreased appetite, and weight loss. Seven patients died during the trial, and four cases may be related to the investigational drug.This study reveals that bendamustine hydrochloride is a feasible treatment option for the indolent B-cell non-Hodgkin lymphoma patient who has not remitted or relapsed after treatment with rituximab. All adverse events were predictable and manageable.© 2022 American Cancer Society.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
共同第一作者：
通讯作者：
通讯机构： [1]Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. [2]Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. [*1]Department of Medical Oncology, Fudan University Shanghai Cancer Center, No 270 Dong'an Road, Xuhui District, Shanghai 200032, China. [*2]Sun Yat‐Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
推荐引用方式(GB/T 7714)：
Gao Yan,Liu Yizhen,Wang Yafei,et al.Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China[J].CANCER.2023,129(4):551-559.doi:10.1002/cncr.34544.
APA：
Gao Yan,Liu Yizhen,Wang Yafei,Zhang Qingyuan,Wu Depei...&Huang Huiqiang.(2023).Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.CANCER,129,(4)
MLA：
Gao Yan,et al."Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China".CANCER 129..4(2023):551-559

相关文献

[1]An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) [2]Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001) [3]Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients [4]Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study. [5]The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103) [6]Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: A systematic review and meta-analysis of randomized controlled trials. [7]Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer [8]Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC) [9]Efficacy and safety of camrelizumab combined with TACE for hepatocellular carcinoma: a systematic review and meta-analysis [10]Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号